JYSELECA is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent.
A simple choice. JYSELECA 200 mg is a convenient, efficacious and rapid treatment that is generally well tolerated1,2
Rapid symptomatic improvement (nominal p<0.05 vs. placebo, post hoc analysis):1
Achieved Week 58 clinical remission (p<0.0001, primary endpoint), histologic remission and ≥6-month corticosteroid-free clinical remission (p<0.0001 and p<0.01, respectively, secondary endpoints)2
JAK1-preferential inhibitor that has been generally well tolerated, with a consistent safety profile across clinical trials2
References: 1. Danese S, Ferrante M, Feagan BG, et al. Am J Gastroentrol 2022;118:138–147. 2. Feagan BG, Danese S, Loftus EV Jr, et al. Lancet 2021;397:2372–2384. 3. Feagan BG, Matsuoka K, Rogler G, et al. ECCO 2023. OP35. 4. Schreiber S, Feagan BG, Peyrin-Biroulet L, et al. J Crohn's Colitis 2023;jjad018.
GB-UC-JY-202303-00003 | Date of preparation: April 2023
Adverse events should be reported.
For Great Britain, reporting forms and information can be found at yellowcard.mhra.gov.uk or via the Yellow Card app (download from the Apple App Store or Google Play Store). Adverse events should also be reported to Galapagos via email to DrugSafety.UK.Ireland@glpg.com or 0800 072 7878.
Adverse events should be reported.
For Northern Ireland, reporting forms and information can be found at yellowcard.mhra.gov.uk or via the Yellow Card app (download from the Apple App Store or Google Play Store). Adverse events should also be reported to Galapagos via email to DrugSafety.UK.Ireland@glpg.com or 0800 072 7878.
Adverse events should be reported.
For the Republic of Ireland, reporting forms and information can be found at www.hpra.ie and can be reported to HPRA on +353 1 6764971.
Adverse events should also be reported to Galapagos via email to DrugSafety.UK.Ireland@glpg.com or 00800 7878 1345.
Jyseleca, Galapagos and the Galapagos logo are registered trademarks of Galapagos NV.
GB-IBD-FIL-202211-00008
Date of preparation: November 2023
Contact Us
Galapagos Biotech Ltd
148 Belmont Rd, Uxbridge UB8 1QS
medicalinfo@glpg.com
Jyseleca, Galapagos and the Galapagos logo are registered trademarks of Galapagos NV.
GB-IBD-FIL-202211-00008
Date of preparation: November 2023
Contact Us
Galapagos Biotech Ltd
148 Belmont Rd, Uxbridge UB8 1QS
medicalinfo@glpg.com
© 2023 Galapagos NV. All rights reserved.
This link will take you away from the Galapagos website and you will be re-directed to a non-Galapagos website. Galapagos does not accept liability for sites controlled by third-parties.